Business Wire

Dexcom Showcases Accuracy, Simplicity and Connectivity of Its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally

Share

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the strength of its CGM portfolio and unveil new clinical and real-world evidence that continues to demonstrate the effectiveness of Dexcom CGM at the 16th International Conference on Advanced Technologies and Treatments for Diabetes held Feb. 22-25, 2023 in Berlin.

“Last year at ATTD we first introduced our expanded portfolio of Dexcom CGM systems,” said Jake Leach, executive vice president and chief operating officer of Dexcom. “Almost one year later we are thrilled to report that Dexcom G7 is already available in eight countries, Dexcom ONE has played a significant role in helping expand CGM coverage for millions more people with diabetes and Dexcom G6 continues to lead the industry in connectivity with automated insulin delivery systems and digital health apps.”

Dexcom G7, the most powerful and simple CGM, is now available in the United States, Germany, the United Kingdom, Ireland, Austria, Hong Kong, New Zealand and South Africa with additional launches planned in 2023. Feedback from initial Dexcom G7 users has been extremely positive, with consistent praise for the 60% smaller wearable,* shortest warmup period on the market and more engaging and consumer-friendly mobile app. In addition, 97% of initial users surveyed found Dexcom G7 easy to use.2

Dexcom ONE continues to help expand access to CGM globally by providing a simple and accurate‡,3 option to meet the diverse needs of customers, clinicians, and payers around the world. This has been a key element of the company’s global access initiatives, which expanded reimbursed coverage to Dexcom CGM outside the US by more than 3.5 million lives over the past 18 months. From Spain to Estonia and the UK, more and more people living with diabetes are gaining access to real-time CGM as Dexcom ONE continues to launch in additional markets.

Dexcom G6 is the most connected CGM system in the world,4 with hundreds of thousands of users now connected to insulin pumps, pens and digital health apps.§ Dexcom’s ecosystem enables greater customer choice through partnerships with multiple automated insulin delivery systems and an API infrastructure that allows connectivity to several digital health partners, such as Garmin, Sugarmate, Glooko and Happy Bob. The company’s connectivity platform is helping make diabetes management more convenient than ever before for Dexcom G6 users.

In addition, new clinical and real-world evidence continues to affirm the use of Dexcom CGM is central to optimal diabetes management, while helping to expand CGM access and use in new populations. Some of the most recent evidence showcasing the effectiveness of Dexcom CGM will be highlighted in posters, presentations and during the Dexcom Symposia at ATTD.

Dexcom Symposia Overview

Dexcom Continues to Lead in CGM Technology Across the Diabetes Spectrum
Thursday, February 23, 2023, 3:00 – 4:30 PM CET, in Plenary Hall A6
Moderated by Daniel Chernavvsky, MD

  • This education program will focus on Dexcom CGM and its use with both Type 1 and Type 2 diabetes patients. Real world experience and correlational outcomes of Dexcom G7 and its unique features will be shared, as well as an introduction to the new 2GO-CGM study, focusing on the use of Dexcom CGM use in Type 2, intensive and non-intensive insulin treated patients. Finally, the next generation Dexcom-TypeZero AID algorithm and first in-human study results will be presented.

Dexcom CGM: Transforming the Course of Care for Type 2 Diabetes
Friday, February 24, 2023, 8:00 – 8:50 AM CET, in Hall A3
Moderated by Noriko Kodani, MD, PhD

  • This program reviews recently updated clinical practice guidelines on rtCGM use in Type 2 diabetes management. There will be a presentation highlighting new data on the use of rtCGM early in the course of care for Type 2 diabetes. Additionally, there will be an examination on how improving access for people with Type 2 diabetes, on less intensive insulin regimens are positioned to impact utilization and adoption of rtCGM in clinical practice. Finally, there will be a review of ways to simplify the review of CGM data, specifically for Type 2 diabetes, and steps that have been taken to integrate Dexcom Clarity data into electronic health records for more efficient clinical workflows.

Ahead of the Curve: Inpatient Use of Dexcom G6 and Automated Insulin Delivery Systems
Friday, February 24, 2023, 4:40 – 6:00 PM CET, in Hall A5
Moderated by Erin Cobry, MD

  • The emergence of diabetes technology in the hospital holds the potential to revolutionize glycemic management and change the standard of care. In this session, participants will learn how these technologies are fueling the possibility in different patient populations and hospital settings. The esteemed panel will discuss continuation of Dexcom rtCGM upon hospital admission and an associated accuracy analysis in the pediatric population, preservation of intensive care unit capacity by using Dexcom G6 in a stepdown unit for patients admitted with diabetic ketoacidosis, feasibility of an automated insulin delivery system in patients with Type 1 or Type 2 diabetes in a medical-surgical unit, and perioperative use of fully closed-loop insulin delivery.

For more information about these presentations and to register to virtually attend the conference, visit https://attd.kenes.com/ .

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information on Dexcom, visit https://www.dexcom.com/en-us/about-dexcom.

*Compared to a prior generation Dexcom CGM System.
Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
Results obtained with Dexcom G6 study, which uses the same applicator and sensor (and algorithm) as Dexcom ONE.
§To learn more about insulin pump integrations and compatibility with Dexcom CGM Systems, visit dexcom.com/integrate.

1 Dexcom G7, Dexcom G6 and Dexcom ONE CGM System User Guides.
2 Dexcom, data on file, 2021.
3 Shah V et al. Diabetes Technol Ther. 2018;20(6):428-433.
4 Dexcom, data on file, 2022.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Grid Dynamics Wins Two MACH Impact Awards for Best Retail Project and Best Overall Change Project19.6.2024 23:05:00 EEST | Press release

Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and advanced analytics services, proudly announces that it has been awarded MACH Impact Awards for Best Retail Project and Best Overall Change Project at the MACH THREE conference, held in New York City on June 17-18, 2024. This annual conference of the MACH Alliance is home of the MACH Impact Awards, honoring MACH (Microservices, API-first, Cloud-native, and Headless) strategies and implementations that solve technical challenges and create rapid return-on-investment. Grid Dynamics’ recognition in two categories is a reflection of its co-innovation with long-time client and global footwear brand, Clarks. The awards highlight Grid Dynamics’ exceptional ability to help clients craft innovative MACH-based solutions that create substantial business impact. “To have the most significant and challenging digital modernisation Clarks has ever undertak

Verimatrix XTD Dashboard Evolves: Revolutionizing Risk Visibility, Tracking, and Actionability19.6.2024 18:45:00 EEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced major enhancements to its XTD dashboard, providing customers with greater visibility into application security risks and more actionable insights to better protect mobile apps and users. First launched in early 2022, the updated XTD dashboard introduces an all new risk classification model that replaces numerical scores with four clear implication classifications -- Informational, Low, Suspicious and High. This allows security teams to quickly understand the severity and context around detected threats. Detailed explanations accompany each risk level, ensuring transparency. In addition to the new risk scoring model, the XTD dashboard provides specific remediation guidance mapped to each risk level. Teams can immediately see recommended steps for investigating, applying protections or addressing vulnerabilities based on the evaluated threat

Evexta Bio appoints Shawn M. Leland as Chairman of the Board of Directors19.6.2024 18:07:00 EEST | Press release

Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, announces the appointment of Shawn M. Leland, PharmD, RPh as Chairman of the Board of Directors. Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. Throughout his career, Shawn has successfully advanced novel oncology assets and programs, raised substantial capital for various ventures, negotiated major global licensing agreements, and established strategic partnerships. His extensive experience in leading biotech startups, raising capital and executing strategic collaborations will be a major benefit to Evexta Bio in its growth and corporate development strategy. Most recently, Shawn was the Interim CEO and Board Director of ForeBio, where he led the company through a phase 2 study with registrational intent and closed a $75M Series D financing. In July 2019, Shawn founded Elevation Oncology, where

euNetworks refinances part of its existing debt and secures additional sustainability-linked debt funding commitment to drive continued growth19.6.2024 15:57:00 EEST | Press release

euNetworks Holdings Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has completed the refinancing of existing debt as well as raising significant undrawn, committed debt facilities. This will fund the construction and development of the next generation of critical bandwidth infrastructure in Europe. The new long-term infrastructure financing solution provides total debt facilities of €1,260 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240619905010/en/ Katherine Alexakis, Chief Financial Officer, euNetworks (Photo: Business Wire) euNetworks builds and invests in city and long haul fibre networks to connect key European data centres and data hubs. The company owns and operates deep fibre networks in 18 cities as well as a highly differentiated long haul network that spans 45,000 route kilometres across 17 countries. As a specialist in the sector, euNetworks contin

Scientist.com Unveils Elisa: An LLM-Powered Research Assistant for Scientists in the Pharmaceutical and Biotechnology Industries19.6.2024 14:55:00 EEST | Press release

Scientist.com, the world’s leading marketplace for biopharma research, today announced the launch of a new large language model (LLM)-powered research assistant called Elisa, named in homage to a widely used research assay and to ELIZA, an early 1960s chatbot. Elisa is the newest addition to a suite of proprietary AI-powered apps created by Scientist.com to improve and accelerate drug research. Marketplace users can now benefit from a powerful, scalable, and intuitive LLM assistant that understands the nuances of pharmaceutical research and has been trained on Scientist.com’s public data sources. “Elisa is a bridge between advanced technology and our customers, providing them with instant access to marketplace information and a conversational interface that understands their research needs,” said Chris Petersen, Founder and CTO of Scientist.com. “It’s the latest in a series of LLM-powered tools we’ve built to help life science researchers run their drug discovery programs faster and at

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye